Literature DB >> 11606114

Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.

J Belinson1, Y L Qiao, R Pretorius, W H Zhang, P Elson, L Li, Q J Pan, C Fischer, A Lorincz, D Zahniser.   

Abstract

OBJECTIVE: The aim of this study was to design a cervical cancer screening algorithm for the developing world that is highly sensitive for cervical intraepithelial neoplasia (CIN) II, III, and cancer and highly specific for CIN II and III, making it possible to ablate the transformation zone without histologic confirmation.
METHODS: In rural Shanxi Province, China, we examined 1997 women ages 35-45. Each subject underwent a self-test for intermediate and high-risk HPV (by HC-II assay), fluorescence spectroscopy, a liquid-based Pap (read manually and by computer and used as a direct test for HPV), a visual inspection (VIA) diagnosis, and colposcopy with multiple cervical biopsies.
RESULTS: Mean age was 39.1 +/- 3.16 years, mean number of births was 2.6 +/- 0.93. Based on tests administered, 4.3% subjects had > or =CIN II. All subjects with > or =CIN II had either a ThinPrep Pap (> or =ASCUS) or a positive HPV direct test. The sensitivity and specificity for the detection of > or =CIN II were, respectively, 83 and 86% for the HPV self-test, 95 and 85% for the HPV direct test, 94 and 78% for the ThinPrep Pap (> or =ASCUS), 77 and 98% for the ThinPrep Pap (> or =HGSIL), 94 and 9% for fluorescence spectroscopy, 71 and 74% for VIA, and 81 and 77% for colposcopy.
CONCLUSION: Based on these data and the existing healthcare infrastructure in China, we believe that further refinement of primary HPV screening using centralized labs is indicated. Self-testing in the local villages may be effective with improvements in the devices and techniques. Copyright 2001 Academic Press.

Entities:  

Mesh:

Year:  2001        PMID: 11606114     DOI: 10.1006/gyno.2001.6370

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  57 in total

1.  Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.

Authors:  Fang-Hui Zhao; Margaret Jane Lin; Feng Chen; Shang-Ying Hu; Rong Zhang; Jerome L Belinson; John W Sellors; Silvia Franceschi; You-Lin Qiao; Philip E Castle
Journal:  Lancet Oncol       Date:  2010-11-11       Impact factor: 41.316

2.  Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Authors:  Li C Cheung; Qing Pan; Noorie Hyun; Mark Schiffman; Barbara Fetterman; Philip E Castle; Thomas Lorey; Hormuzd A Katki
Journal:  Stat Med       Date:  2017-06-28       Impact factor: 2.373

3.  Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples.

Authors:  Akhila Balasubramanian; Shalini L Kulasingam; Atar Baer; James P Hughes; Evan R Myers; Constance Mao; Nancy B Kiviat; Laura A Koutsky
Journal:  J Low Genit Tract Dis       Date:  2010-07       Impact factor: 1.925

4.  Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China.

Authors:  Margaret Z Wang; Rui-Mei Feng; Shaoming Wang; Xian-Zhi Duan; Dong Li; Xun Zhang; Rong Mu; Youlin Qiao; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2019-08       Impact factor: 2.830

5.  SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China.

Authors:  Suzanne E Belinson; Na Wulan; Ruizhen Li; Wei Zhang; Xuan Rong; Yasha Zhu; Ruifang Wu; Jerome L Belinson
Journal:  Int J Gynecol Cancer       Date:  2010-08       Impact factor: 3.437

6.  Vaginal Self-Sampling for Human Papillomavirus Infection as a Primary Cervical Cancer Screening Tool in a Haitian Population.

Authors:  Joel C Boggan; David K Walmer; Gregory Henderson; Nahida Chakhtoura; Schatzi H McCarthy; Harry J Beauvais; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2015-11       Impact factor: 2.830

7.  Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses.

Authors:  Shao-Ming Wang; Danny Colombara; Ju-Fang Shi; Fang-Hui Zhao; Jing Li; Feng Chen; Wen Chen; Shu-Min Li; Xun Zhang; Qin-Jing Pan; Jerome L Belinson; Jennifer S Smith; You-Lin Qiao
Journal:  Int J Gynecol Cancer       Date:  2013-05       Impact factor: 3.437

8.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

9.  Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Authors:  Patti E Gravitt; Proma Paul; Hormuzd A Katki; Haripriya Vendantham; Gayatri Ramakrishna; Mrudula Sudula; Basany Kalpana; Brigitte M Ronnett; K Vijayaraghavan; Keerti V Shah
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

10.  A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria.

Authors:  Kayode Olusegun Ajenifuja; Julia C Gage; Akinfolarin C Adepiti; Nicolas Wentzensen; Claire Eklund; Mary Reilly; Martha Hutchinson; Robert D Burk; Mark Schiffman
Journal:  Int J Gynecol Cancer       Date:  2013-03       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.